{
    "Clinical Trial ID": "NCT01591746",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Group A - Botulinum Toxin Type A",
        "  100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast",
        "  Botulinum Toxin Type A",
        "INTERVENTION 2: ",
        "  Group B - Placebo",
        "  5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast",
        "  Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women at least 18 years of age, who will undergo immediate unilateral or bilateral tissue expander breast reconstruction following therapeutic skin-sparing or nipple-sparing mastectomy",
        "  Women at least 18 years of age, who will undergo immediate bilateral tissue expanders breast reconstruction following risk-reduction (prophylactic) skin-sparing or nipple-sparing mastectomy",
        "Exclusion Criteria:",
        "  Subjects who are unable to read or speak English",
        "  Breast reconstruction using the latissimus dorsi flap combined with a tissue expander",
        "  Documented diagnosis of chronic pain, upper limb spasticity, cervical dystonia, axillary hyperhidrosis, strabismus or blepharospasm",
        "  Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation",
        "  Infection at the proposed site of injection",
        "  Pre-existing neuromuscular disorders (including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis)",
        "  Aminoglycosides intake at the time of surgery (these antibiotics can potentiate the effect of BTX-A)",
        "  Women who are pregnant or breast feeding",
        "  Presence of breast implants from previous breast surgery",
        "  Reported use of Botox within 4 months prior to planned surgical date"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale",
        "  The numeric pain intensity scale (NPIS) will be completed at the preoperative visit and again at the first postoperative visit. The NPIS is a visual analog scale (VAS) commonly used to assess clinical pain. Subjects are asked to rate their pain on a scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.",
        "  Time frame: preoperative visit, first postoperative visit (1-2 weeks post surgery)",
        "Results 1: ",
        "  Arm/Group Title: Group A - Botulinum Toxin Type A",
        "  Arm/Group Description: 100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast",
        "  Botulinum Toxin Type A",
        "  Overall Number of Participants Analyzed: 68",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: score on a scale  2        (1.5 to 4)",
        "Results 2: ",
        "  Arm/Group Title: Group B - Placebo",
        "  Arm/Group Description: 5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast",
        "  Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A",
        "  Overall Number of Participants Analyzed: 63",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: score on a scale  3        (2 to 4)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/68 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}